The composition and form of issue:
1 tablet contains finasteride 5 mg, in a contour acheikova packing 14 PCs., in box 1 or 2 packaging.
Inhibits 5-alpha-reductase, reduces the biosynthesis of dihydrotestosterone.
It is well absorbed and penetrates the tissues and bioliquids, including in the ejaculate.
Description pharmacological action:
The chronic administration of a statistically significant effect is registered after 3 months (reduction of volume of the prostate), 4 months (increase in the maximum flow rate of urine) and 7 months (reduction of General symptoms and symptoms of obstruction of the urinary tract).
Suppressing the formation of dihydrotestosterone accompanied by a decrease of prostate volume, increase the maximum flow rate of urine and reducing the symptoms of obstruction of the urinary tract.
Ineffective in patients with malignant degeneration of the prostate gland (cancer).
Adenoma of the prostate gland.
Hypersensitivity, children’s age.
Application of pregnancy and breast-feeding:
Pregnant women should avoid contact with crushed or lost the integrity of the tablets. Women who may become pregnant, pregnant women and nursing mothers should not have sexual intercourse (without a condom) with a partner taking proscar (possibly impaired development of the external genital organs in male fetus).
Violation of sexual function (impotence, decreased libido, reduced ejaculate volume).
Clinically significant effects of interactions with other drugs not detected.
Method of application and dose:
Inside, 5 mg/day for 6-7 months or more.
Patients with large residual urine volume and/or sharply reduced its current, it is necessary to closely monitor the possible development of obstructive uropathy.
|Manufacturer||Merck Sharp & Dohme|
|The purpose of the medication||Androgens, Anti-androgens|